Authors


Jeffrey Freiberg, MD, PhD

Latest:

2024 S aureus and MRSA Trials: Key Takeaways

Jeffrey Freiberg, MD, PhD review of the SABATO trial on oral antibiotics for S aureus bacteremia and a comparison of mupirocin and iodine treatments for MRSA decolonization.


Myriam Shaw Ojeda, PharmD

Latest:

Assisting With International Health Care Needs

Although the pandemic halted many medical mission assignments, these opportunities and others are becoming available to help those geographic areas with acute needs.


Gerard Jacinto, PharmD

Latest:

Should Cefazolin be Prescribed in Patients With B-lactam Allergies?

For patients undergoing surgery, looking at the potential benefits of this antimicrobial for prophylaxis.


Chelsea Gulden

Latest:

National Youth HIV/AIDS Awareness Day Reminds Young People They Are Not Forgotten

During these uncertain times, RAIN President and CEO Chelsea Gulden talks about the importance of taking a grassroots approach to HIV advocacy to work with young people in the local communities who are either dealing with the virus or are susceptible to it.


Mahmud Sheku, MPH, MSc

Latest:

Maternal RSV Vaccines Show Promise for Infant Protection but Raise Safety Concerns

New meta-analysis at the 2025 vaccinology conference highlights the efficacy of maternal RSV vaccines, with calls for enhanced monitoring following safety issues with one candidate


Stacy Lindborg, PhD

Latest:

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants

Stacy Lindborg, PhD, highlights the vaccine’s immune response, safety, and global distribution potential.


Syra Madad, DHSc, MSc, MCP, CHEP

Latest:

Strategies for Improving Pandemic Preparedness

Syra Madad, DHSC, MSc, MCP, CHEP, outlines early surveillance systems and diagnostic innovations for enhancing pandemic management and response.


Meagan Adamsick O’Brien, PharmD, BCIDP

Latest:

Defining the Characteristics of Breakthrough Invasive Fungal Infections in Hematologic Disorders

This systematic review focuses on breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological cancers, like acute leukemia, or those who have undergone stem cell transplants. Despite prophylactic antifungal treatments (usually with voriconazole or posaconazole), bIFIs remain challenging due to their complexity and high mortality rates.


Brian Nowosielski

Latest:

Simplifying Vaccine Access Translates to Better Uptake

Investigators evaluated strategies to simplify the vaccination process to yield higher rates of adult immunization, similar to that of the COVID-19 pandemic.


Meghan Lyman, MD

Latest:

Candida auris: Coming Soon to a Facility Near You?

Epidemiologic and clinical lessons for the uninitiated.


Addison Benee Taylor, PharmD

Latest:

Multidrug Resistance in a Patient With HIV

In this case study, clinicians review a challenging case.


Anthony Weinstock, DO

Latest:

Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid Antibiotic

Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.


Amy L. Carr, PharmD, BCIDP

Latest:

The Next Generation of COVID-19 Vaccines and Boosters

Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?


Greg Mario, MBA, CEO

Latest:

Funding Isn’t Everything: Bringing Pharma to the Table for the Pasteur Act

The pharmaceutical industry faces challenges when investing in new antibiotics, which emphasizes the need for regulatory reforms, incentives, and collaborative efforts between government, healthcare organizations, and private companies. The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies.


Kyle H. Lee

Latest:

That’s Not Appropriate: A Look at Antibiotic Prescribing Post Discharge

Extending antimicrobial stewardship programs to transition of care and discharge may prove beneficial to reduce unnecessary antibiotic use.


Jacinda C. Abdul-Mutakabbir, PharmD, MPH

Latest:

Health Equity is Essential to Overcoming Antimicrobial Resistance

The antimicrobial resistance (AMR) crisis stems from natural microbial adaptation and the lack of new antimicrobials in development. Vulnerable populations worldwide, including within the US, are disproportionately affected, exacerbating the spread of resistance.


Sophia Abene

Latest:

Top 5 Infectious Disease News Stories Week of June 28-July 5

This week, Moderna’s mRNA-1010 flu vaccine showed strong phase 3 results, new research reveals that FMT may fail due to functional mismatches between donor microbes and the recipient’s gut, and more.


Marissa Cavaretta, PharmD, BCPS, BCACP

Latest:

Sticking It to COVID-19: The Expansion of the Pfizer-BioNTech Vaccine EUA

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.


Kelly Cawcutt, MD, MS, FACP, FIDSA, FCCM

Latest:

Opposing Forces During COVID-19: Perspective From the ICU

Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.


Maureen McElligott, MD

Latest:

Opposing Forces During COVID-19: Perspective From the ICU

Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.


Sandra Perreand, MBA

Latest:

Lifting the Medical and Economic Burden of AMR in the US

This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.


Elysia Burke, PharmD

Latest:

Febrile Finesse: Are We Employing Appropriate Empiric Coverage in Patients With Neutropenic Fever?

Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.


Audry Hawkins, PharmD

Latest:

SHARE the Responsibility of Antibiotic Stewardship With Our Patients

How pharmacists can use shared decision-making to improve antibiotic use.


Lindsey M. Childs-Kean, PharmD, MPH, BCPS

Latest:

Updates in the Treatment of Mycobacterium Tuberculosis

The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.


Andrew Skinner, MD

Latest:

Key Takeaways on FMTs in the Treatment of CDI

Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.



Alexandra L. Cunha, PharmD

Latest:

The Next Generation of COVID-19 Vaccines and Boosters

Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?


Caroline Teter, PA-C

Latest:

Lessons in Resilience: What HIV Teaches Us About COVID-19

Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.


John Rex, MD, FACP

Latest:

New Antifungal Drug Olorofim Shows Efficacy in Treating Resistant Fungal Infections

John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.


David Angulo, MD

Latest:

Second-Generation Antifungal Aims to Address Invasive Fungal Disease

Scynexis developed its investigational fungal compound, SCY-247, which is in phase 1 clinical trials, and the company expects to share top-line data this year.

© 2025 MJH Life Sciences

All rights reserved.